Keystone Nano said today that it has begun clinical testing for its ceramide NanoLiposome cancer therapy. The Phase I trial plans to evaluate the company’s NanoLiposome as a targeted treatment for solid tumors.
Ceramide is a lipid that has demonstrated efficacy in liver cancer, breast cancer, leukemia and pancreatic cancer. Preclinical evidence has shown that the NanoLiposome is an effective delivery system for the bioactive compound, targeting cancer cells and ignoring healthy cells, according to the State College, Penn.-based company.
Get the full story at our sister site, Drug Delivery Business News.
The post Keystone Nano launches clinical trial for NanoLiposome cancer therapy appeared first on MassDevice.
from MassDevice http://ift.tt/2oJazwr
Cap comentari:
Publica un comentari a l'entrada